focus -WSS

focus

author：Wikipedia 2025-09-30 05:11:56 Page View：2

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date
Next article： Medical leaders decry Supreme Court decision on affirmative action

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Covid vaccine financial winners and losers, from Pfizer to Novavax

Illustration:ChristineKao/STAT;Photos:GettyIt’sbeenfouryearssinceCovid-19emerged,ignitingapandemicth

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Parkland mass shooting to be reenacted for lawsuit

0:49The"1200building"atMarjoryStonemanDouglasHighSchool,thecrimescenewherethe2018shootingstookplace,